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Abstract  
Purpose: Development of secondary central nervous system involvement (SCNS) in 
patients with diffuse large B-cell lymphoma (DLBCL) is associated with poor outcomes. The 
CNS International Prognostic Index (CNS-IPI) has been proposed for identifying patients at 
greatest risk, but the optimal model is unknown.  
Methods: We retrospectively analyzed patients with DLBCL diagnosed between 2001-
2013, staged with PET/CT and treated with R-CHOP(-like) regimens. Baseline 
clinicopathologic characteristics, treatments, and outcome data were collected from clinical 
databases and medical files. We evaluated the association between candidate prognostic 
factors and modeled different risk models for predicting SCNS.  
Results: Of 1,532 patients, 62 (4%) subsequently developed SCNS. By multivariate 
analysis, disease stage III/IV, elevated serum LDH, kidney/adrenal, and uterine/testicular 
involvement were independently associated with SCNS. There was a strong correlation 
between absolute number of extranodal sites and risk of SCNS; the 144 patients (9%) with 
>2 extranodal sites had a 3-year cumulative incidence of SCNS of 15.2% (95%CI 9.2-21.2%) 
compared with 2.6% (95%CI 1.7-3.5) among those with ≤2 sites (P<0.001). The 3-year 
cumulative risks of SCNS for CNS-IPI defined risk groups were 11.2%, 3.1%, and 0.4% for 
high, intermediate and low risk patients, respectively. All risk models analyzed had high 
negative predictive values, but only modest positive predictive values.  
Conclusions: Patients with >2 extranodal sites or high-risk disease according to the CNS-
IPI should be considered for baseline CNS staging. Clinical risk prediction models suffer 
from limited positive predictive ability, highlighting the need for more sensitive biomarkers to 
identify patients at highest risk of this devastating complication.  
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Highlights: 
 Risk of CNS relapse in diffuse large B-cell lymphoma is predicted by the CNS-IPI  
 The CNS-IPI remains valid in PET/CT staged diffuse large B-cell lymphoma 
 More than two extranodal sites at diagnosis confers increased risk of CNS relapse 
Keywords: Diffuse large B-cell lymphoma, PET/CT, CNS-IPI, CNS relapse, secondary CNS 
involvement, CNS prophylaxis, Prognosis 
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Introduction 
Patients with secondary CNS involvement (SCNS) by diffuse large B-cell lymphoma 
(DLBCL) have a dismal prognosis, highlighting the pressing need for effective preventative 
strategies.(1-11) The addition of CNS-penetrating chemotherapeutics such as high-dose 
methotrexate (HDMTX) into frontline protocols appears the most promising prophylactic 
strategy and has been recommended by recent guidelines.(10, 12, 13) Clinical risk factors 
for SCNS are well characterized and have been used to construct risk models, which allow 
targeted application of such prophylaxis.(2-4, 14, 15) The CNS-IPI, the best validated of 
these, combines established International Prognostic Index (IPI) risk factors (age >60 years, 
stage III/IV disease, >1 extranodal site, ECOG performance score >1, and LDH above upper 
normal limit) with kidney/adrenal involvement into a 6-point score with high-risk patients 
defined by a total score of ≥4.(16) Disease stage and extranodal involvement are consistent 
risk factors for SCNS in most analyses, but their association with SCNS may be influenced 
by the imaging modality used for baseline staging. In DLBCL, PET/CT detects more 
extranodal disease sites than conventional staging and this leads to upstaging in a relevant 
number of patients.(17) The aims of this study were to examine risk factors for SCNS, and 
validate the CNS-IPI model in a large independent cohort of PET/CT staged patients treated 
with R-CHOP or R-CHOP-like regimens 
 
Patients and Methods 
This retrospective study included patients from clinical databases (Guy's and St Thomas' 
Hospital [London] and Peter MacCallum Cancer Centre [Melbourne]) or from regional 
(British Columbia Cancer Agency [BCCA] Centre for Lymphoid Cancer Database 
[Vancouver BC]) and national (Danish Lymphoma Registry [LYFO]) lymphoma registries. 
Data collection was compliant with national and local regulations. 
The patients were diagnosed with DLBCL between 2001 and 2013, but the surveyed time 
period varied between the centers according to the availability of PET/CT and database 
characteristics. Patients fulfilling the following criteria were included: a) treatment-naïve 
DLBCL, b) R-CHOP(-like) therapy, and c) staging with PET/CT. Baseline CNS staging 
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procedures varied according to site, however CNS imaging or cerebrospinal fluid (CSF) 
evaluation were not required for inclusion. Patients with known CNS involvement at the time 
of diagnosis (parenchymal, leptomeningeal, or intraocular) were excluded. Patients 
coincidentally diagnosed with discordant involvement of the bone marrow by a low-grade 
lymphoma during staging work-up for DLBCL were allowed in the study. Medical records 
and/or databases were reviewed for clinical characteristics and patient outcome. PET/CT 
reports were reviewed by a clinician investigator at each site for staging information. Multiple 
lesions within one organ or tissue type (i.e. multiple skeletal or hepatic lesions) were 
considered a single extranodal site. Bone marrow involvement was defined as focal lesions 
in the bone marrow on staging PET/CT and/or bone marrow biopsy positive for DLBCL.(18)  
Patients treated with R-CHOP or similar regimens (R-CEOP [rituximab, cyclophosphamide, 
etoposide, vincristine, prednisone] and R-CHOEP [R-CHOP with etoposide]) were included. 
Radiotherapy and CNS prophylaxis were administered according to local policy in place at 
time. Common indications for radiotherapy included limited stage DLBCL in combination 
with abbreviated R-CHOP, bulky disease, or solitary extranodal lesions. The strategies for 
CNS prophylaxis included intrathecal chemotherapy (typically MTX ± cytarabine ± 
methylprednisolone), systemic high-dose antimetabolite therapy (MTX or cytarabine), or 
both intrathecal and systemic therapy. The indications cited for CNS prophylaxis included 
involvement of specific extranodal sites (including kidney/adrenal and testicular 
involvement), sites with anatomic proximity to the CNS, and elevated LDH in combination 
with advanced stage disease/extensive extranodal involvement. As evaluation of CNS 
prophyalxis was not the primary focus of the study, we did not collect information regarding 
doses or timing of CNS prophylaxis delivered. During the inclusion period, however, it was 
common practice to delivered IT prophalxis synchronously with R-CHOP(-like) treatment 
whereas systemic prophylaxis was given after completion of R-CHOP in many cases. 
SCNS was defined as DLBCL relapse within the brain parenchyma, leptomeninges, spinal 
cord, or eye (intra-vitreous only). Pathological or cytological verification of SCNS was not 
mandatory in the presence of compatible clinical and radiologic findings.  
 
Statistical analyses  
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Patient characteristics were summarized using descriptive statistics and compared using 
appropriate tests. Time to SCNS was defined as time from initial diagnosis of lymphoma to 
date of first SCNS. The cumulative incidence of SCNS was estimated using Fine and Gray’s 
competing risk regression and death without SCNS was treated as a competing risk.(19) 
However, interpretating estimated effect parameters obtained in a Fine and Gray’s approach 
as cause-specific SCNS risk is complicated and the effect of the covariates on the cause-
specific hazard was estimated using Cox proportional hazards models with censoring of 
deaths before SCNS. The variables with P ≤0.15 in univariate analyses were entered in a 
multivariate Cox proportional hazards model. Increased risk of SCNS with uterine 
involvement by DLBCL was previously reported in an analysis of female patients in this 
cohort and was included in the Cox analyses to adjust for confounding.(20) The CNS-IPI 
risk model was compared with other models in explorative analyses. Risk of SCNS 
associated with international prognostic index (IPI) >2 was also included in this analysis.(21) 
Since there was overlap between the 86 BCCA patients included in the present study and 
those included in the CNS-IPI validation study, all BCCA patients were excluded from the 
validation of the CNS-IPI presented in this study.(16) The statistical programming language 
R version 3.2.2 was used for all statistical analyses.  
 
Results 
In total, 1,532 DLBCL patients were included (Denmark n=1088, BCCA n=86, Guy's and St 
Thomas' Hospital n=147, and Peter MacCallum Cancer Centre n=211). Baseline 
demographics and treatment information are shown in Table 1. With a median follow-up 
from diagnosis of 40 months, the 3-year PFS and OS rates were 72% (95% CI 70,75%) and 
78% (95% CI 76,80%), respectively. Overall, 1520/1532 (99.2%) patients underwent staging 
bone marrow biopsy and 90 (5.9%) of those patients had morphologic bone marrow 
involvement by a low-grade lymphoma. 
Sixty-two patients (4%) developed SCNS at a median of 9 months (range 2-78) from initial 
diagnosis (Figure 1A). SCNS occurred during first-line treatment in nine patients (15%), at 
first relapse 41 (66%) and at second or subsequent relapse in 12 (19%). At the time of 
SCNS, 20 (32%) also had systemic disease. SCNS was documented solely by CSF cytology 
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in 15 (24%), imaging in 36 (58%), both in 10 (16%) and one patient had intravitreal relapse. 
Among those with imaging documented SCNS without positive CSF, 18 (50%) had 
confirmatory brain biopsy; overall 69% of cases were histologically confirmed. Among the 
late SCNS events (>60 months after first pathologic diagnosis of DLBCL), 3/3 had biopsy 
documented SCNS.  
The 3-year cumulative risk of SCNS according to specific clinicopathological features and 
the results of Cox analyses are shown in Table 2. In multivariate analysis, stage III/IV, 
elevated LDH, involvement of kidney/adrenal, and reproductive organs (uterus/testis) was 
significantly associated with SCNS. Infiltration by indolent lymphoma in the bone marrow 
was not associated with increased risk of SCNS.  
The CNS-IPI risk group distribution is shown in Table 1. In an analysis excluding all patients 
from BCCA (previously included in another validation study(16)), the 3-year cumulative 
incidence of SCNS was 11% (95% CI 7,15%) in the high-risk group, 3% (95% CI 2,4%) in 
the intermediate-risk group, and 0.4% (95% CI 0,1%) in the low-risk group (Fig 1B).  
Involvement of >1 extranodal site, as defined in the IPI score, was not an independent risk 
factor for SCNS in the patients included in the testing cohort of the recent CNS-IPI 
publication.(16) In an exploratory analysis, we analyzed the risk of SCNS associated with 
increasing number of extranodal sites detected on staging PET/CT (Figure 2A and Table 3). 
There was an incremental increase in the risk of SCNS with increasing total number of 
extranodal sites detected. According to the classifier performance curves (not shown), 
sensitivity and specificity were balanced using a cut-off >2 extranodal sites and the 
cumulative incidence of SCNS using this cut-off is shown in Figure 2B. The sensitivity, 
specificity, positive predictive value (PPV), and negative predictive value (NPV) of different 
CNS risk models are presented in Table 4. The performance of the CNS-IPI risk model was 
tested against a simple model for SCNS using >2 extranodal sites, IPI>2, and the risk model 
proposed by Boehme et al. in Table 2.(3, 16) Relative to the CNS-IPI, the >2 extranodal 
sites model defined fewer patients as high-risk, had higher specificity and overall accuracy, 
but lower sensitivity. Among patients with >2 extranodal sites, 105/143 (73%) were also 
high-risk according to the CNS-IPI. For patients with >2 extranodal sites who did not met the 
CNS-IPI high-risk definition, 3/38 patients (8%) suffered SCNS. Among the three latter 
patients, none had kidney/adrenal or testis involvement, but one had uterine involvement by 
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DLBCL. The PPV was low (10-15%) for all tested models and the overall accuracy was 
poorest when using IPI>2 as the  high-risk defining feature (Table 4). In an analysis including 
the clinicpathologic features independently associated with SCNS (Table 2), >2 extranodal 
sites remained independently associated with SCNS (HR 2.52 [95%CI 1.32,4.80] P=0.005). 
Among patients witth >2 extranodal sites, 6/78 men had testicular involvement and 34/144 
of all had kidney involvement.  
In a separate analysis of elderly DLBCL patients (>70 years), the 3-year cumulative 
incidence of SCNS in low, intermediate, and high-risk CNS-IPI were 0% (95%CI 0.0,0.0), 
2.2% (95%CI 0.3,4.1), and 9.0% (95%CI 4.1,14.0), respectively. Thus, in elderly patients 
the CNS-IPI remained a valid tool for SCNS risk stratification. 
Among CNS-IPI high-risk patients, 98/292 (33.6%) received CNS prophylaxis (26 systemic, 
33 intrathecal, and 39 both). The cumulative incidences of SCNS for CNS-IPI high-risk 
patients treated with or without systemic CNS prophylaxis who attained at least a PR 
following first-line treatment (to avoid guarantee time bias) were similar (3-year SCNS rates 
were 11.2% (95%CI 10.8,11.6) for patients treated with systemic CNS prophylaxis +/- IT 
prophylaxis versus 10.2% (95%CI 10.0,10.3) for patients treated without systemic CNS 
prophylaxis, (log-rank test; P=0.84).  
 
Discussion 
This study highlights the role of PET/CT in identifying DLBCL patients at increased risk of 
SCNS after R-CHOP chemotherapy. In exploratory analysis of the SCNS risk associated 
with extranodal DLBCL, we observed a striking proportional correlation between the 
PET/CT-detected absolute number of extranodal sites of involvement and risk of SCNS. 
While the association between extranodal dissemination in DLBCL (>1 extranodal site) and 
SCNS has been reported,(8) the marked increase in risk with an increase in the absolute 
number of extranodal sites has not previously been reported to our knowledge. It is possible 
the increased risk of SCNS in patients featuring involvement of multiple extranodal sites may 
be driven by the presence of associated biological factors such as dual translocations of 
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MYC and BCL2 rearrangements and/or MYC/BCL2 co-expression, however, data on these 
variables were unavailable for the majority of patients in our study.(22)  
We did not find an increased risk of SCNS among patients with involvement of breast or 
sinus/orbital structures, but our analyses may be biased, as 34/53 patients (64%) with sinus 
and/or orbital involvement and 7/35 patients (20%) with breast involvement received CNS 
prophylaxis. Consistent with our results, however, patients with craniofacial involvement 
undergoing immunochemotherapy in German trials did not have increased risk of SCNS.(23) 
Large cell involvement of the bone marrow may fall into a similar category: It was described 
in pre-rituximab series(8) to be a risk factor for SCNS, but data from rituximab treated 
patients are less concordant with some studies suggesting it remains a predictor(4) and 
others not.(24) Other specific extranodal sites of involvement such as the testis was not 
included in the CNS-IPI risk model despite data from large retrospective series comprised 
exclusively of patients with primary testicular lymphoma that indicated 5-year cumulative 
incidence of 19%.(25) This is likely explained by the under-representation of such patients 
in the population from which the original CNS-IPI was derived. Consistently, testicular 
involvement was associated with significantly increased risk of SCNS in multivariable 
analysis in the present study despite widespread use of CNS prophylaxis for this group of 
patients. Recent data suggests, that female reproductive organ involvement appears 
similarly associated with increased SCNS risk, although this is not consistently found in all 
study populations.(16, 20, 26, 27)  
We compared the performance of several risk models in our cohort. The CNS-IPI was 
originally developed in patients treated on prospective clinical trial protocols, but has now 
been validated in two large independent cohorts comprising patients treated at both 
community and academic centers.(16) Consequently, the proportion of patients (263/2164 
[12.1%]) in the original German study classified as high-risk (score 4-6) was substantially 
lower than in the two validation studies: 344/1597 (21.5%) in the BCCA cohort, and 
276/1433 (19%) in the present study.(16) Nevertheless, the CNS-IPI has produced 
remarkably consistent risk estimates in three studies collectively including approximately 
5,300 patients receiving chemoimmunotherapy, making it the most robust index developed 
to date. It also successfully predicted risk of SCNS in the elderly DLBCL patients (>70 years) 
in the present study. However, it has several limitations.  In our cohort, a CNS-IPI score≥4 
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had excellent NPV (98%), moderate sensitivity (56%) and specificity (82%), but poor PPV 
(12%) raising concerns of overtreatment if selecting patients for systemic CNS prophylaxis 
based on this score alone. All risk models examined performed poorly in this regard: using 
a cut-off of >2 extranodal sites of involvement by PET we observed a PPV of 15% and 
specificity of 92% at the cost of reduced sensitivity (36%). Using the original IPI score (IPI 
score >2 as high-risk defining feature), the sensitivity was significantly better than other 
models, but the specificity was lower leading to problematic overtreatment if IPI>2 is used 
as indication for CNS prophylaxis. The difficulty of developing clinical useful models arises 
from the low incidence of SCNS and the relative low HR associated with individual risk 
factors. This emphasizes the need to identify and prospectively validate more precise 
biomarkers for SCNS to improve stratification of intermediate and high risk groups. However, 
the molecular, immunologic or cellular mechanisms underlying SCNS remain poorly 
understood. Geng et al performed a series of experiments using an integrated approach 
suggesting a possible role for B- and T-lymphocyte attenuator (BTLA) in mediating 
SCNS.(28) These observations, while intriguing, remain conjectural and require 
confirmation. Similar to CNS prophylaxis, applying rigorous baseline screening for CNS 
involvement in high-risk patients may also reduce the number of SCNS cases substantially. 
For example, the addition of flow-cytometry analysis of CSF increase the detection rate of 
discrete baseline CNS involvement by 6% in patients evaluated with lumbar puncture.(29) 
We observed no significant difference in the crude rate of SCNS among the 61 CNS-IPI 
high-risk patients who received systemic CNS directed prophylaxis relative to the 155 
patients who did not (3-year cumulative SCNS risk 11.2 vs. 10.2%, P=0.84 – only patients 
achieving at least PR included in this analysis). It is important to note that this study was not 
designed to assess the impact of CNS prophylaxis; as such, we did not collect detailed 
information regarding dose, schedule and timing. During the inclusion period, it was common 
practice many places to deliver systemic CNS prophylaxis after completing R-CHOP, but a 
recent prospective study suggest that early HDMTX interponated between the first R-CHOP 
cycles may reduce risk of SCNS substantially for younger high-risk patients.(30) Also, there 
were likely biases and confounding factors in why these patients were selected to receive 
such prophylaxis. Evidence regarding the efficacy of this modality are somewhat conflicting. 
Data from two studies, one retrospective(31) and one prospective (32) suggest the use of 
high-dose antimetabolites may not reduce SCNS. In contrast, data from several other 
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retrospective (7, 10, 13) and prospective (33) studies do suggest a risk reduction. Therefore, 
for patients with high risk CNS-IPI, involvement of specific high-risk sites, and possibly also 
those with >2 extranodal sites by PET/CT who do not fulfill other high-risk criteria, we 
continue to advocate systemic CNS prophylaxis be considered.  
Our study has weaknesses. We did not perform central PET/CT or pathology review, and in 
most cases, immunohistochemical stains (MYC, BCL2, Ki-67) and fluorescence in situ 
hybridization for rearrangements in MYC, BCL2 and BCL6 were not performed. In many 
cases, PET/CT scans were jointly reviewed by nuclear medicine specialists and radiologists 
and consensus conclusions made. Given the multi-centre nature of the study and timespan 
included, we cannot provide the exact interpretation criteria used in each case. Baseline 
lumbar puncture and CNS imaging of the brain were also not routinely performed, thus, we 
cannot be exclude the possibility that a few SCNS patients had occult CNS disease at the 
time of initial diagnosis. The above limitations are shared by other large SCNS database 
studies.(3, 4, 16) Furthermore, information about HIV status was unavailable, although the 
populations included had low prevalence for HIV infection. Systemic CNS prophylaxis was 
used in 13% of the patients included in the present study. Although systemic CNS 
prophylaxis did not completely eliminate the risk of SCNS in the CNS-IPI high risk patients 
in our study, the inclusion of these patients may have affected the analysis. Nonetheless, 
our data reflect a real world population in which many patients with high CNS-IPI do routinely 
receive CNS-directed prophylaxis and thus still has relevance.  
In conclusion, we have confirmed the robust ability of the CNS-IPI to predict CNS relapse in 
a large independent cohort of patients and demonstrated that the risk of CNS relapse 
increases proportionally with the absolute number of PET-detected extranodal sites. 
Patients with DLBCL and >2 extranodal sites may also be relevant for CNS staging and 
consideration of systemic prophylaxis, independent of CNS-IPI. This finding requires 
validation in an independent cohort.  
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Tables  
Table 1: Clinic-pathological features of 1,532 patients with diffuse large B-cell lymphoma 
staged with PET/CT and treated with R-CHOP(-like) therapy. 
Characteristic N (%) 
Median age, years (range) 65 (17-92) 
Male:female ratio 1.26 
Ann Arbor Stage, N (%) 
 I 
 II 
 III 
 IV 
  
298 (19%) 
275 (18%) 
303 (20%) 
656 (43%) 
Extranodal sites, N (%) 
 0 sites 
 1 site 
 2 sites 
 3 sites 
 ≥4 sites 
 
590 (39%) 
567 (37%) 
231 (15%) 
92 (6%) 
52 (3%) 
Elevated serum LDH, N (%)* 755 (49%) 
B-symptoms, N (%)* 593 (39%) 
R-IPI risk groups, N (%)* 
 Very good (score 0) 
 Good (score 1-2) 
 Poor (score 3-5) 
 
176 (12%) 
729 (48%) 
614 (40%) 
CNS-IPI risk group, N (%)* 
 Low(score 0-1) 
 Intermediate(score 2-3) 
 High (score 4-6) 
 
513 (34%) 
714 (47%) 
292 (19%) 
Frontline immunochemotherapy, N (%) 
 R-CHOP 
 R-CHOEP 
 R-CEOP 
  
1395 (91%) 
105 (7%) 
32 (2%) 
Radiation therapy, N (%) 513 (34%) 
CNS prophylaxis, N (%) 
 Systemic alone 
 Intrathecal alone 
 Systemic and intrathecal 
 None 
 
77 (5%) 
129 (8%) 
118 (8%) 
1208 (79%) 
*Patients with missing values: LDH = 11, B-symptoms = 24, R-IPI score = 13, and CNS-IPI score = 13. 
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Table 2: 3-year cumulative incidences for secondary CNS (SCNS) involvement and hazard 
ratio (HR) for SCNS associated with a variety of clinic-pathological features. Factors with 
P≤0.15 in univariate analyses were included in the multivariate analysis. 
 Number 
of 
patients, 
n (%) 
3-yr Cumulative 
risk of SCNS, % 
(95%CI) 
Univariate Analyses Multivariate Analysis 
(95%CI) 
HR (95% CI) P HR (95% CI) P 
Age > 60 years 971 (63%) 5 (3,6) 1.86 (1.05,3.29) 0.03 1.49 (0.82,2.70) 0.19 
Stage III/IV disease 959 (63%) 6 (4,7) 13.33 (4.18,42.53) <0.001 5.49 (1.6,18.92) 0.007 
B-symptoms 593 (39%) 5 (3,7) 1.75 (1.05,2.90) 0.03 0.80 (0.46,1.37) 0.41 
>1 extranodal site 375 (24%) 8 (5,11) 3.93 (2.39,6.47) <0.001 0.94 (0.48,1.84) 0.86 
Elevated serum LDH 766 (50%) 6 (5,8) 5.86 (2.97,11.54) <0.001 3.94 (1.90,8.18) <0.001 
ECOG performance status >1 236 (15%) 6 (3,9) 1.96 (1.08,3.56) 0.03 1.02 (0.53,1.94) 1 
 Liver 129 (8%) 7 (3,12) 3.21 (1.71,6.03) <0.001 1.80 (0.88,3.66) 0.11 
Kidney/adrenal 64 (4%) 14 (6,23) 5.27 (2.68,10.38) <0.001 3.36 (1.57,7.19) 0.002 
Breast 35 (2%) 3 (0,9) 1.43 (0.35,5.85) 0.62   
Sinus 42 (3%) 8 (0,16) 1.78 (0.56,5.68) 0.33   
Bone marrow#  437 (29%) 7 (4,9) 2.99 (1.81,4.92) <0.001 1.47 (0.83,2.59) 0.18 
Discordant bone marrow#  90 (6%) 4 (0,8) 0.89 (0.28,2.84) 0.84   
Testis 48 (6%)* 7 (0,15) 2.55 (0.87,7.53) 0.10 5.15 (1.61,16.53) 0.003 
Uterus 17 (3%)* 41 (17,66) 16.41 (6.13,43.90) <0.001 15.68 (5.03,48.88) <0.001 
Thyroid 35 (2%) 11 (1,22) 3.18 (1.15,8.76) 0.03 2.30 (0.79,6.70) 0.13 
Orbits 23 (2%) 5 (0,14) 1.14 (0.16,8.23) 0.9   
#Bone marrow involvement ascertained by focal lesions on PET/CT and/or bone marrow biopsy (only DLBCL). Discordant bone marrow 
involvement was defined as infiltration by an indolent lymphoma diagnosed at the time of DLBCL. 
* Number of patients with uterus or testis involvement is relative to the male and female cohorts, respectively. 
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Table 3: Relationship between number of extranodal disease sites and risk of secondary 
CNS involvement. 
Number of 
extranodal 
sites, n 
Number of 
patients,  
n (%)  
3-year 
cumulative 
risk of SCNS, 
% (95% CI) 
Univariate 
analysis, 
HR (95% CI) 
Multivariate 
analysis, 
HR (95% CI) 
0 590 (39%) 2 (0,3) 1 (ref) 1 (ref) 
1 567 (37%) 3 (2,5) 3.03 (1.35,6.81) 2.97 (1.26,7.00) 
2 231 (15%) 4 (1,6) 3.64 (1.44,9.24) 1.54 (0.52,4.60) 
3 92 (6%) 9 (3,15) 9.65 (3.71,25.07) 3.59 (1.14,11.30) 
≥4 52 (3%) 25 (13,38) 25.80 (10.67,62.37) 11.37 (3.77,34.25) 
*Multivariate analysis including adjustment for elevated LDH, age>60 years, and ECOG 
performance>1. Stage III/IV disease and kidney/adrenal disease was not included due to 
their intrinsic relationship with extranodal disease. 
 
Table 4: Sensitivity, specificity, accuracy, positive predictive value, and negative predictive 
value of different CNS relapse risk models and >2 extranodal sites.  
 CNS-IPI 
High risk 
ECOG 
performance>1 + >1 
extranodal site + 
elevated LDH 
(Boehme et al.) (3) 
P* >2 extranodal 
sites 
P* >2 IPI P* 
Proportion of high risk patients 292/1519 
(19.2%) 
84/1519 (5.5%) <0.001 144/1532 (9.5%) <0.001 614/1519 
(40.4%) 
<0.001 
SCNS according to risk 
 
 High risk 
 Non-high risk 
 
 
34/292 (11.6%) 
27/1227 (2.2%) 
 
 
9/84 (10.7%) 
52/1435 (3.6%) 
 
 
1 
0.039 
 
 
22/144 (15.3%) 
40/1388 (2.9%) 
 
 
0.29 
0.32 
 
 
46/614 (7.5%) 
15/905 (1.7%) 
 
 
0.045 
0.43 
Sensitivity (95% CI) 55.7 
(42.4,68.5) 
14.8 (7.0,26.2) <0.001 35.5 (23.7,48.7) 0.005 75.4 (62.7,85.5) <0.001 
Specificity (95% CI) 82.3 
(80.2,84.2) 
94.9 (93.6,95.9) <0.001 91.7 (90.2,93.1) <0.001 61 (58.5,63.6) <0.001 
Positive predictive value (95% 
CI) 
11.6 (8.2,15.9) 10.7 (5.0,19.4) 0.75 15.3 (9.8,22.2) 0.1 7.5 (5.5,9.9) <0.001 
Negative predictive value (95% 
CI) 
97.8 
(96.8,98.5) 
96.4 (95.3,97.3) <0.001 97.1 (96.1,97.9) 0.04 98.3 (97.3,99.1) 0.07 
Accuracy (95% CI) 81.2 
(79.2,83.2) 
91.6 (90.1,93.0) <0.001 89.4 (87.8,90.9) <0.001 61.6 (59.1,64.1) <0.001 
*P values reflect comparisons of model by Boehme at al. and >2 extranodal sites model to the CNS-IPI model.  
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